Aarey Drugs & Pharmaceuticals working capital

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

34.94×	34.94×	31.66×	30.34×	132.32×	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
100.19×	100.19×	49.91×	87.55×	952.55×
54.50×	54.50×	72.32×	122.47×	792.79×
80.63×	80.63×	9.25×	−4.58×	292.08×
3.52×	4.01×	4.07×	−5.64×	0.61×
1.76×	1.76×	1.74×	1.33×	0.23×
2.56×	2.56×	2.40×	1.68×	−79.06×
1.41×	1.41×	4.29×	1.77×	−25.57×

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

AAREYDRUGS₹110.84

Aarey Drugs & Pharmaceuticals Limited

· Pharma & Health

₹ CrorePeersNECLIFE NATCAPSUQ MEDICAMEQ MEDICO BALPHARMA ALPA KREBSBIO HALEOSLABSMcap ₹315 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Inventory Days (DIO)	132.32	30.34	31.66	34.94	34.94
Receivable Days (DSO)	952.55	87.55	49.91	100.19	100.19
Payable Days (DPO)	792.79	122.47	72.32	54.50	54.50
Cash Conversion Cycle (days)	292.08	-4.58	9.25	80.63	80.63
Working Capital Turnover	0.61	-5.64	4.07	4.01	3.52
Asset Turnover	0.23	1.33	1.74	1.76	1.76
Cash Conversion (CFO/Net Income)	-79.06	1.68	2.40	2.56	2.56
CFO/EBITDA	-25.57	1.77	4.29	1.41	1.41

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.